158. Tuberous sclerosis Clinical trials / Disease details


Clinical trials : 108 Drugs : 67 - (DrugBank : 17) / Drug target genes : 35 - Drug target pathways : 118

  
5 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02849457
(ClinicalTrials.gov)
December 201613/7/2016Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis ComplexPreventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex (PREVeNT Trial) A Randomized, Double-blind, Placebo-controlled Seizure Prevention Clinical Trial for Infants With TSCTuberous Sclerosis ComplexDrug: Vigabatrin;Drug: PlaceboMartina BebinNational Institute of Neurological Disorders and Stroke (NINDS)Active, not recruitingN/A6 MonthsAll84Phase 2United States
2EUCTR2013-005528-40-BE
(EUCTR)
11/12/201417/11/2014Long-term, prospective study evaluating clinical and molecular biomarkers of epileptogenesis in a genetic model of epilepsy – tuberous sclerosis complexLong-term, prospective study evaluating clinical and molecular biomarkers of epileptogenesis in a genetic model of epilepsy – tuberous sclerosis complex - EPISTOP epilepsy in tuberous sclerosis complex (TSC);Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Trade Name: vigabatrin (sabril)
Product Name: vigabatrin
INN or Proposed INN: VIGABATRIN
Vrije Universiteit BrusselNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
100Belgium;Netherlands
3EUCTR2013-005528-40-NL
(EUCTR)
05/12/201414/07/2014Long-term, prospective study evaluating clinical and molecular biomarkers of epileptogenesis in a genetic model of epilepsy – Tuberous Sclerosis Complex.Long-term, prospective study evaluating clinical and molecular biomarkers of epileptogenesis in a genetic model of epilepsy – Tuberous Sclerosis Complex. - EPISTOP Epilepsy in tuberous sclerosis complex (TSC)
MedDRA version: 17.0;Level: LLT;Classification code 10032061;Term: Other forms of epilepsy;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Vigabatrin (Sabril)
Product Name: vigabatrin
The Children's Memorial Health InstituteNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
100Belgium;Netherlands
4NCT01266291
(ClinicalTrials.gov)
August 201022/12/2010Sabril for Complex Partial Seizures in Adult Tolerability Study (TS) PatientsSabril for Treatment of Adult Refractory Partial Seizures Symptomatic of Tuberous Sclerosis: An Open Label, Phase IV Prospective Safety and Tolerability StudyComplex Partial SeizuresDrug: vigabatrinUniversity of PennsylvaniaH. Lundbeck A/STerminated18 YearsN/AAll1Phase 4United States
5EUCTR2020-003231-19-PL
(EUCTR)
09/10/2020Comparison of the efficacy and safety of rapamycin versus vigabatrin in the prevention of Tuberous Sclerosis Complex symptoms in infants in the randomized clinical trialRandomized, placebo-controlled, double-blind and double-dummy clinical trial comparing the safety, tolerability, and efficacy of vigabatrin and rapamycin in a preventive treatment of infants with Tuberous Sclerosis Complex (ViRap) - ViRap Tuberous Sclerosis ComplexEpilepsyTumors associated with Tuberous Sclerosis Complex;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Trade Name: SABRIL 500 mg, granules for oral solution
Trade Name: RAPAMUNE 1 mg/ml oral solution
The Children's Memorial Health InstituteNULLNAFemale: yes
Male: yes
60Phase 2;Phase 3Poland